OmniaBio Inc

OmniaBio is a technology-focused contract development and manufacturing organisation (CDMO) specialising in cell and gene therapies. They offer comprehensive services that encompass the entire product lifecycle, from preclinical development to large-scale commercial manufacturing. ​

Established as a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM), OmniaBio leverages over a decade of manufacturing and analytical expertise to advance regenerative medicine. Their mission is to prioritise client partnerships and manufacturing innovation to improve patients' lives worldwide. With state-of-the-art facilities in Toronto and Hamilton, Ontario, OmniaBio is strategically positioned to serve North American and global markets. ​

Key Products and Services

Process Development: Expert optimisation to ensure reliable scale-up of cell and gene therapies. ​

Analytical Development: Comprehensive services offering tailored and established assays. ​

GMP Manufacturing: Resilient and scalable manufacturing through to commercial supply. ​

Autologous Cell Therapy Manufacturing: Advanced solutions for personalised therapies. ​

Cell Banking: Secure storage solutions for cell lines. ​

Regulatory Guidance: Expert navigation through the regulatory landscape to approval. ​

Supply Chain Security: Ensuring integrity and reliability in the supply chain. ​

OmniaBio stands at the forefront of cell and gene therapy manufacturing, committed to delivering innovative and scalable solutions. Their dedication to advancing the field ensures that clients can confidently progress their therapeutic programmes, ultimately improving patient access to transformative treatments